Business Description
Theravance Biopharma Inc
NAICS : 325412
SIC : 2834
ISIN : KYG8807B1068
Description
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 2.08 | |||||
Equity-to-Asset | 0.56 | |||||
Debt-to-Equity | 0.23 | |||||
Debt-to-EBITDA | -1.15 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -1.66 | |||||
Beneish M-Score | -2.61 | |||||
WACC vs ROIC |
Growth Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -3.4 | |||||
3-Year EBITDA Growth Rate | 44.9 | |||||
3-Year EPS without NRI Growth Rate | 41.1 | |||||
3-Year FCF Growth Rate | 49.4 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 53.12 | |||||
9-Day RSI | 54.95 | |||||
14-Day RSI | 55.31 | |||||
6-1 Month Momentum % | -3.51 | |||||
12-1 Month Momentum % | -20.67 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 5.39 | |||||
Quick Ratio | 5.39 | |||||
Cash Ratio | 4.14 | |||||
Days Sales Outstanding | 100.91 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 9.2 | |||||
Shareholder Yield % | 114.62 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -94.05 | |||||
Net Margin % | -96.12 | |||||
FCF Margin % | -51.42 | |||||
ROE % | -17.79 | |||||
ROA % | -11.56 | |||||
ROIC % | -22.71 | |||||
ROC (Joel Greenblatt) % | -83.68 | |||||
ROCE % | -10.39 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 8.65 | |||||
PB Ratio | 2.08 | |||||
Price-to-Tangible-Book | 2.08 | |||||
EV-to-EBIT | -8.4 | |||||
EV-to-EBITDA | -9.23 | |||||
EV-to-Revenue | 6.86 | |||||
EV-to-Forward-Revenue | 5.5 | |||||
EV-to-FCF | -13.36 | |||||
Price-to-Median-PS-Value | 0.5 | |||||
Earnings Yield (Greenblatt) % | -11.9 | |||||
FCF Yield % | -6.59 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Theravance Biopharma Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 53.23 | ||
EPS (TTM) (€) | -0.9 | ||
Beta | -0.05 | ||
Volatility % | 27.56 | ||
14-Day RSI | 55.31 | ||
14-Day ATR (€) | 0.190744 | ||
20-Day SMA (€) | 8.6075 | ||
12-1 Month Momentum % | -20.67 | ||
52-Week Range (€) | 7.6 - 10.6 | ||
Shares Outstanding (Mil) | 48.56 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Theravance Biopharma Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Theravance Biopharma Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Theravance Biopharma Inc Frequently Asked Questions
What is Theravance Biopharma Inc(FRA:0TB)'s stock price today?
When is next earnings date of Theravance Biopharma Inc(FRA:0TB)?
Does Theravance Biopharma Inc(FRA:0TB) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |